Humacyte

We care about the impact we make to biotech in RTP. In a recent article in Triangle Business Journal, we share the importance of staying close to intellectual talent because R&D is at our core. As our CEO, Dr. Laura Niklason, puts it, “Every professor or biomedical scientist that works on clinically relevant things always dreams of bringing their inventions to patients, getting something on the market and approved”. Let’s continue to innovate and make a difference together! Learn more at https://humacyte.com Follow us to stay updated on the latest. #Humacyte #Innovation #Biotech

The future of companies like Humacyte, Liquidia Corporation and Verona Pharma will play a crucial role in the future of North Carolina's #biotech industry. We took a look at how each company is faring as they seek FDA approval for their drugs and treatments. #lifesciences #pharma #rtp #researchtriangle #raleigh #durham #northcarolina #drugmakers #pharmaceuticals

We love a good podcast! Our Founder and CEO, Laura Niklason, MD, PhD recently joined Jacob Goldstein @pushkinpods on the “What’s Your Problem?” podcast to delve into the science behind the investigational Acellular Tissue Engineered Vessel (ATEV™). During their conversation, they explored: The Science of ATEV: They dove into the details and steps for our innovative technology and research about the ATEV and shared thoughts on the potential to make an impact from the battlefields or violent events and on to the hospitals. Insightful: This discussion was a retelling of an intriguing 20 year journey and a great listen with interesting anecdotes and great conversation between Laura and Jacob. Tune in to the podcast to gain deeper insights into these exciting developments! https://lnkd.in/eHNEKw8Y #MedicalInnovation #Vascular #HealthcareAdvances #Podcast #Humacyte #FutureOfMedicine #Biotech photo courtesy of Pushkin Podcasts

Thank You to Our 10,000 LinkedIn Followers! Your enthusiasm for our mission has been incredible. At Humacyte, we’re advancing a potential future where our bioengineered tissues and organs may transform medicine. Stay tuned and share the news as we continue to make strides in clinical trials, FDA designations, and beyond. Here’s to progress, innovation, and the next 10,000 supporters!

Today we announced the strengthening of our Board of Directors with two impactful leaders, John Bamforth PhD and Keith A. (Tony) Jones, MD. They have abundant experience in commercialization and health systems to guide us as we approach the anticipated launch of our investigational ATEV™ for vascular trauma repair. Read more about their impressive backgrounds and our upcoming plans here: https://lnkd.in/eCz-gQ6a   #Humacyte #HealthcareInnovation #BoardOfDirectors #ATEV #Biotech 

Humacyte’s Acellular Tissue Engineered Vessel, a bioengineered regenerative vessel, is currently in clinical trial phases as a universally implantable vascular conduit that is non-immunogenic and that resists infection after implantation. Designed to be ready off-the-shelf, the ATEV has the potential to save valuable time for surgeons who treat injured patients, and to improve outcomes and reduce complications. The ATEV has accumulated more than 1,200 patient-years of experience worldwide in a series of clinical trials in multiple indications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral artery disease. The US Food and Drug Administration (FDA) accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the ATEV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible. The FDA’s BLA decision is targeted for August 10, 2024. The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. Watch the video here: https://lnkd.in/dUseJchf For more information, visit www.Humacyte.com. ™ Indicates a trademark of Humacyte Global, Inc. © 2024 Humacyte Global, Inc. All Rights Reserved This video was filmed by Humacyte and is being sponsored for distribution in association with Vascular News and CX Vascular. Biba Medical bears no responsibility for the assets used in the production of this video. #ATEV #AcellularTissueEngineeredVessel #Humacyte #ArterialRepair

Pluristyx, Inc. is thrilled to be working with Humacyte to pave the way for groundbreaking advancements in insulin-dependant diabetes treatment.   Under this partnership, Humacyte has licensed Pluristyx’s clinical-grade PluriBank™ induced pluripotent stem cell (iPSC) line for use in their BioVascular Pancreas (BVP™) program. As part of the program, Humacyte intends to implant islet cells derived from this iPSC line into their proprietary Acellular Tissue Engineered Vessels (ATEV™).   The partnership also provides access to Pluristyx’s panCELLa™ platform, which enables the creation of “hypoimmune” cells with a drug-inducible kill-switch designed for safe clinical implantation. Pluristyx will be performing custom clinical gene editing on the iPSC line to generate this universal line.   This agreement highlights Pluristyx’s continued commitment to bringing Tomorrow's Cell Therapies, Today®, by ensuring safety and efficacy through our PluriBank™ cell lines and panCELLa™ platform.   Learn more about the partnership here: https://lnkd.in/gTdQAQZj

We have received a lot of positive feedback surrounding our recent press release. In a recent article, Triangle Business Journal expands on our announcement that the FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) designation for Humacyte’s technology, Acellular Tissue Engineered Vessels (ATEV™), for patients with advanced peripheral artery disease (PAD). The article highlights include a comment from our CEO and Founder, Dr. Laura Niklason, our technology, and our facilities. TBJ has kept up with us in the past and has written several articles about Humacyte’s advances. We appreciate that a local publication like Triangle Business Journal is staying informed about our progress. If you are a member, look us up and enjoy a good read. Humacyte Press Release https://lnkd.in/eXJSG6sy TBJ Article https://lnkd.in/eZFGwTFM

Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for its investigational acellular tissue engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This RMAT designation was granted at the same time as the FDA cleared a new Investigational New Drug (IND) application for the PAD indication for ATEV, formerly referred to as the human acellular vessel (HAV). Read more: https://lnkd.in/e3aSRmjS

Happy 4th of July from Humacyte! Stay safe and enjoy the holiday with your friends and family. #July4th #Humacyte